ATE320481T1 - Prozess zur herstellung reifer dendritischer zellen und eines impfstoffes - Google Patents

Prozess zur herstellung reifer dendritischer zellen und eines impfstoffes

Info

Publication number
ATE320481T1
ATE320481T1 AT02758675T AT02758675T ATE320481T1 AT E320481 T1 ATE320481 T1 AT E320481T1 AT 02758675 T AT02758675 T AT 02758675T AT 02758675 T AT02758675 T AT 02758675T AT E320481 T1 ATE320481 T1 AT E320481T1
Authority
AT
Austria
Prior art keywords
poly
dendritic cells
mature dendritic
vaccine
producing mature
Prior art date
Application number
AT02758675T
Other languages
English (en)
Inventor
Malcolm Adams
Cyril Donninger
Original Assignee
Bioclones Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioclones Pty Ltd filed Critical Bioclones Pty Ltd
Application granted granted Critical
Publication of ATE320481T1 publication Critical patent/ATE320481T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02758675T 2001-08-08 2002-08-08 Prozess zur herstellung reifer dendritischer zellen und eines impfstoffes ATE320481T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0119346.5A GB0119346D0 (en) 2001-08-08 2001-08-08 Process for the maturation of dendritic cells

Publications (1)

Publication Number Publication Date
ATE320481T1 true ATE320481T1 (de) 2006-04-15

Family

ID=9920030

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758675T ATE320481T1 (de) 2001-08-08 2002-08-08 Prozess zur herstellung reifer dendritischer zellen und eines impfstoffes

Country Status (14)

Country Link
US (1) US7981673B2 (de)
EP (1) EP1417300B1 (de)
JP (1) JP2004538000A (de)
AT (1) ATE320481T1 (de)
AU (1) AU2002324255B2 (de)
BR (1) BR0212016A (de)
CA (1) CA2457322C (de)
DE (1) DE60209915T2 (de)
DK (1) DK1417300T3 (de)
ES (1) ES2263806T3 (de)
GB (1) GB0119346D0 (de)
MX (1) MXPA04001152A (de)
WO (1) WO2003014335A1 (de)
ZA (1) ZA200401842B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258712A3 (de) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
WO2005043155A1 (en) 2003-10-21 2005-05-12 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
AU2006322073A1 (en) * 2005-12-07 2007-06-14 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
AU2013206335B2 (en) * 2005-12-07 2017-05-04 Hemispherx Biopharma, Inc. dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants
US8129184B2 (en) 2006-09-26 2012-03-06 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
BRPI0808637A2 (pt) * 2007-03-05 2014-08-05 Univ Utah State Agonista restritivo do receptor 3 similar a toll (tlr3)
WO2009088401A2 (en) * 2007-09-24 2009-07-16 Government Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Immunostimulatory combinations of tlr ligands and methods of use
NZ587371A (en) * 2008-02-15 2012-12-21 Hemispherx Biopharma Inc The use of poly(I:C11-14U) for treating bacterial and protozoan infection
EP2281043B1 (de) * 2008-04-25 2013-03-13 Innate Pharma Verbesserte tlr3-agonist-zusammensetzungen
EP2328923B1 (de) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133-epitope
EP2349288A4 (de) * 2008-10-10 2012-08-08 Hemispherx Biopharma Inc Behandlung des chronischen erschöpfungssyndroms mittels selektiver toll-like-rezeptor 3 (tlr3)-agonisten
WO2010047835A2 (en) * 2008-10-23 2010-04-29 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
US10137182B2 (en) 2013-02-14 2018-11-27 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
RU2771104C2 (ru) 2014-05-14 2022-04-26 Таргиммьюн Терапьютикс Аг Улучшенные полиэтилениминовые полиэтиленгликолевые векторы
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CA3097620A1 (en) * 2018-05-04 2019-11-07 Tollys Tlr3 ligands that activate both epithelial and myeloid cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US6080726A (en) * 1985-08-12 2000-06-27 University Of Maryland Anti-viral and immuno stimulator polynucleotide duplex and use thereof
WO1997022349A1 (en) * 1995-12-20 1997-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO2001080887A2 (en) * 2000-04-21 2001-11-01 Chemocentryx, Inc. Methods and chemokin compositions for inducing an immune response

Also Published As

Publication number Publication date
CA2457322C (en) 2014-06-10
DE60209915T2 (de) 2006-12-14
JP2004538000A (ja) 2004-12-24
US20040253722A1 (en) 2004-12-16
BR0212016A (pt) 2004-10-26
ZA200401842B (en) 2005-05-25
DK1417300T3 (da) 2006-07-17
EP1417300A1 (de) 2004-05-12
ES2263806T3 (es) 2006-12-16
EP1417300B1 (de) 2006-03-15
US7981673B2 (en) 2011-07-19
GB0119346D0 (en) 2001-10-03
MXPA04001152A (es) 2005-02-17
CA2457322A1 (en) 2003-02-20
DE60209915D1 (de) 2006-05-11
AU2002324255B2 (en) 2007-06-07
WO2003014335A1 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
ATE320481T1 (de) Prozess zur herstellung reifer dendritischer zellen und eines impfstoffes
JP5797688B2 (ja) ｓｉＲＮＡ接合体及びその製造方法
US8076068B2 (en) Method for determining immunostimulatory activity of RNA oligonucleotides
Lazzarini et al. Covalently linked message and anti-message (genomic) RNA from a defective vesicular stomatitis virus particle
CN105018492B (zh) 不对称干扰rna的组合物及其用途
KR101672563B1 (ko) 안질환을 치료하는 방법
JP2020532955A5 (de)
EP1852506A3 (de) Lipophile Derivate doppelsträngiger Ribonukleinsäure
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
JP2008535493A5 (de)
JP2011500592A5 (de)
HUP0000992A2 (hu) Sejttenyészetben szaporodni képes, géntechnológiailag módosított, fertőző nyálkatömlő-betegséget okozó vírus (IBDV) mutánsai
CN106801068B (zh) 一种自发荧光可降解聚柠檬酸酯的非病毒基因载体及其制备方法
ATE530193T1 (de) Verfahren zur steigerung der klasse i präsentation von exogenen antigene durch humane dendritische zellen
EP1764108A1 (de) Zusammensetzungen enthaltend immunstimulierende RNA-Oligonukleotide und Methoden zu deren Herstellung
ATE342241T1 (de) Verfahren zur herstellung eines glaskeramischen produktes
Jebali et al. Hybridization of different antisense oligonucleotides on the surface of gold nanoparticles to silence zinc metalloproteinase gene after uptake by Leishmania major
EP1258470A3 (de) Verfahren zur Herstellung von optisch-aktiven Alkoholen
ATE517633T1 (de) Neues verfahren und zusammensetzung zur herstellung einer zellulären allogenen vakzine
KR20210095294A (ko) 돼지생식기호흡기증후군 바이러스의 감염력 향상 또는 억제를 위한 돼지 대식세포 분화 및 극성화 방법
ATE286869T1 (de) Verfahren zur herstellung eines diols
EP4183879A1 (de) Doppelsträngiges oligonukleotid und zusammensetzung zur behandlung von covid-19 damit
DE50301697D1 (de) Verfahren zur herstellung von polyetheralkoholen
WO2004019860A3 (en) Formulations of modified antibodies and methods of making the same
CA2298264A1 (en) Haze free polyether polyol compositions and a method for their preparation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1417300

Country of ref document: EP